Our first product is Omalizumab (BP001) which has been produced with our continuous 3C process and developed as a biosimilar through phase I (including extensive comparability exercise with > 30 different assays). Process and product development is combined. Omalizumab is an anti-allergy antibody used against allergic asthma and chronic urticaria. Omalizumab has also been formulated for oral delivery (BOX001) and tested in preclinical experiments. Phase I will start in 2020.